Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 191

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis

Open access
Alexia, Catherine, Fallot, Guillaume, Lasfer, Malika, Schweizer-Groyer, Ghislaine, Groyer, André · 2004 · Biochemical Pharmacology

Abstract

Strong evidence emphasizes the role of the insulin-like growth factor (IGF) system and of type-I IGF receptor (IGF-IR) signalling in tumourigenesis. In this connection: (i) changes in the expression pattern of components of the IGF system (autocrine/paracrine expression of IGF-I and -II, overexpression of IGF-IR, decreased expression of IGF-binding proteins (IGFBPs) and of type-II IGF receptor/cation-independent mannose-6-phosphate receptor (IGF-II/M6PR) and (ii) increased serum concentrations of proteases that cleave the IGFBPs (e.g., cathepsin D) were observed in patients with hepatocellular carcinomas (HCC), in human hepatoma cell lines and in their conditioned culture medium, as well as in rodent models of hepatocarcinogenesis. Accordingly, studies carried out with animal models do suggest that the IGF system and IGF-IR signalling may play a role in hepatocarcinogenesis and in deregulated proliferation and apoptosis of HCC cells. Finally the instrumental role of Raf/MEK/ERK, one of the signalling cascades stimulated by IGF-IR, in anthracycline-induced apoptosis of HepG2 and Huh-7 human hepatoma cell lines emphasizes that care must be taken when designing combinations of antitumoural molecules for antineoplastic treatment. This review addresses the putative roles of the IGF system in primary HCC, with a special focus on the underlying molecular mechanisms. In a second part it emphasizes the putative interference of IGF-IR signalling with chemotherapeutic drug-induced apoptosis in human hepatoma cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bcp.2004.05.029

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 176

  1. Pitot, 1998, Hepatocyte death in hepatocarcinogenesis, Hepatology, 28, 1, 10.1002/hep.510280101 · DOI
  2. Thorgeirsson, 1998, Dysregulation of apoptosis in hepatocellular carcinoma, Semin. Liver Dis., 18, 115, 10.1055/s-2007-1007148 · doi:10.1055/s-2007-1007148
  3. Tannapfel, 2002, Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis, Virchows Arch., 440, 345, 10.1007/s00428-002-0617-x · DOI
  4. Kong, 1996, Quantitative analysis of changes in cell proliferation and apoptosis during preneoplastic and neoplastic stages of hepatocarcinogenesis in rat, Cancer Lett., 105, 241, 10.1016/0304-3835(96)04291-7 · doi:10.1016/0304-3835(96)04291-7
  5. Grasl-Kraupp, 1997, Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression, Hepatology, 25, 906, 10.1002/hep.510250420 · DOI
  6. Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 · DOI · Paper page
  7. Macdonald, 2001, Pathogenesis of hepatocellular carcinoma, Clin. Liver Dis., 5, 69, 10.1016/S1089-3261(05)70154-9 · DOI
  8. Fausto, 1995, Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration, Faseb J., 9, 1527, 10.1096/fasebj.9.15.8529831 · DOI · Paper page
  9. Michalopoulos, 1997, Liver regeneration, Science, 276, 60, 10.1126/science.276.5309.60 · DOI · Paper page
  10. Daughaday, 1989, Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations, Endocr. Rev., 10, 68, 10.1210/edrv-10-1-68 · DOI · Paper page
  11. Humbel, 1990, Insulin-like growth factors I and II, Eur. J. Biochem., 190, 445, 10.1111/j.1432-1033.1990.tb15595.x · DOI · Paper page
  12. Pietrzkowski, 1993, Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1, Cancer Res., 53, 1102
  13. Coolican, 1997, The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways, J. Biol. Chem., 272, 6653, 10.1074/jbc.272.10.6653 · DOI · Paper page
  14. Scrimgeour, 1997, Mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways are not sufficient for insulin-like growth factor I-induced mitogenesis and tumorigenesis, Endocrinology, 138, 2552, 10.1210/endo.138.6.5215 · doi:10.1210/endo.138.6.5215
  15. Baserga, 1994, Oncogenes and the strategy of growth factors, Cell, 79, 927, 10.1016/0092-8674(94)90023-X · DOI · Paper page
  16. Kaleko, 1990, Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation, Mol. Cell Biol., 10, 464
  17. Sell, 1993, Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor, Proc. Natl. Acad. Sci. U.S.A., 90, 11217, 10.1073/pnas.90.23.11217 · DOI · Paper page
  18. Baserga, 2003, The IGF-1 receptor in cancer biology, Int. J. Cancer, 107, 873, 10.1002/ijc.11487 · DOI · Paper page
  19. LeRoith, 2003, The insulin-like growth factor system and cancer, Cancer Lett., 195, 127, 10.1016/S0304-3835(03)00159-9 · DOI · Paper page
  20. Macaulay, 1992, Insulin-like growth factors and cancer, Br. J. Cancer, 65, 311, 10.1038/bjc.1992.65 · DOI · Paper page
  21. Resnicoff, 1994, Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor, Cancer Res., 54, 4848
  22. Resnicoff, 1994, Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors, Cancer Res., 54, 2218
  23. Khandwala, 2000, The effects of insulin-like growth factors on tumorigenesis and neoplastic growth, Endocr. Rev., 21, 215, 10.1210/edrv.21.3.0399 · DOI · Paper page
  24. Sell, 1995, Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis, Cancer Res., 55, 303
  25. Resnicoff, 1995, The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo, Cancer Res., 55, 2463
  26. LeRoith, 1995, Molecular cellular aspects of the insulin-like growth factor I receptor, Endocr. Rev., 16, 143, 10.1210/edrv-16-2-143 · DOI · Paper page
  27. Rubin, 1995, Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity, Lab. Invest., 73, 311
  28. Scott, 1985, Production of insulin-like growth factor I and its binding protein by adult rat hepatocytes in primary culture, Endocrinology, 116, 1094, 10.1210/endo-116-3-1094 · doi:10.1210/endo-116-3-1094
  29. Scharf, 1998, Characterization of the IGF axis components in isolated rat hepatic stellate cells, Hepatology, 27, 1275, 10.1002/hep.510270513 · DOI
  30. Yakar, 1999, Normal growth and development in the absence of hepatic insulin-like growth factor I, Proc. Natl. Acad. Sci. U.S.A., 96, 7324, 10.1073/pnas.96.13.7324 · DOI · Paper page
  31. Boulle, 1993, Developmental regulation of bovine insulin-like growth factor-II (IGF-II) gene expression: homology between bovine transcripts and human IGF-II exons, J. Mol. Endocrinol., 11, 117, 10.1677/jme.0.0110117 · doi:10.1677/jme.0.0110117
  32. Holthuizen, 1993, Transcriptional regulation of the major promoters of the human IGF-II gene, Mol. Reprod. Dev., 35, 391, 10.1002/mrd.1080350412 · doi:10.1002/mrd.1080350412
  33. Holthuizen, 1993, Transcriptional regulation of the human IGF-II gene, Ann. NY Acad. Sci., 684, 214, 10.1111/j.1749-6632.1993.tb32288.x · doi:10.1111/j.1749-6632.1993.tb32288.x
  34. Shimasaki, 1991, Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6), Prog. Growth Factor Res., 3, 243, 10.1016/0955-2235(91)90003-M · DOI · Paper page
  35. Bach, 1992, Insulin-like growth factors and diabetes, Diabetes Metab. Rev., 8, 229, 10.1002/dmr.5610080304 · DOI
  36. Jones, 1995, Insulin-like growth factors and their binding proteins: biological actions, Endocr. Rev., 16, 3
  37. Clemmons, 1997, Insulin-like growth factor binding proteins and their role in controlling IGF actions, Cytokine Growth Factor Rev., 8, 45, 10.1016/S1359-6101(96)00053-6 · DOI · Paper page
  38. Oh, 1993, Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells, J. Biol. Chem., 268, 26045, 10.1016/S0021-9258(19)74273-2 · DOI · Paper page
  39. Leal, 1997, The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor, J. Biol. Chem., 272, 20572, 10.1074/jbc.272.33.20572 · DOI · Paper page
  40. Andress, 1998, Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor, Am. J. Physiol., 274, E744
  41. Ricort, 2002, Insulin-like growth factor binding protein-3 increases intracellular calcium concentrations in MCF-7 breast carcinoma cells, FEBS Lett., 527, 293, 10.1016/S0014-5793(02)03250-7 · doi:10.1016/s0014-5793(02)03250-7
  42. Ricort, 2002, Insulin-like growth factor-binding protein-3 activates a phosphotyrosine phosphatase. Effects on the insulin-like growth factor signaling pathway, J. Biol. Chem., 277, 19448, 10.1074/jbc.M200439200 · DOI
  43. Ricort, 2004, Insulin-like growth factor binding protein-3 stimulates phosphatidylinositol 3-kinase in MCF-7 breast carcinoma cells, Biochem. Biophys. Res. Commun., 314, 1044, 10.1016/j.bbrc.2004.01.001 · doi:10.1016/j.bbrc.2004.01.001
  44. Jones, 1993, Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence, Proc. Natl. Acad. Sci. U.S.A., 90, 10553, 10.1073/pnas.90.22.10553 · DOI · Paper page
  45. Perks, 1999, Effect of insulin-like growth factor binding protein-1 on integrin signalling and the induction of apoptosis in human breast cancer cells, J. Mol. Endocrinol., 22, 141, 10.1677/jme.0.0220141 · DOI
  46. Maile, 1999, Insulin-like growth factor binding protein (IGFBP) proteolysis: occurrence, identification, role and regulation, Growth Horm. IGF Res., 9, 85, 10.1054/ghir.1999.0096 · DOI
  47. Holly, 2000, Overview of insulin-like growth factor physiology, Growth Horm. IGF Res., 10, S8, 10.1016/S1096-6374(00)90003-0 · doi:10.1016/s1096-6374(00)90003-0
  48. Lalou, 1995, A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGF is a cell growth inhibitor, Prog. Growth Factor Res., 6, 311, 10.1016/0955-2235(95)00040-2 · doi:10.1016/0955-2235(95)00040-2
  49. Lalou, 1996, Isolation and characterization of proteolytic fragments of insulin-like growth factor-binding protein-3, Horm. Res., 45, 156, 10.1159/000184779 · DOI
  50. Lalou, 1996, A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin, Endocrinology, 137, 3206, 10.1210/endo.137.8.8754741 · doi:10.1210/endo.137.8.8754741
  51. Scharf, 2001, Regulation of the components of the 150kDa IGF binding protein complex in cocultures of rat hepatocytes and Kupffer cells by 3′,5′-cyclic adenosine monophosphate, J. Cell Physiol., 186, 425, 10.1002/1097-4652(2000)9999:999<000::AID-JCP1036>3.0.CO;2-Y · DOI
  52. Villafuerte, 1991, Nutrition and somatomedin. XXV. Regulation of insulinlike growth factor binding protein 1 in primary cultures of normal rat hepatocytes, Diabetes, 40, 837, 10.2337/diab.40.7.837 · doi:10.2337/diab.40.7.837
  53. Babajko, 1993, Liver-specific expression of human insulin-like growth factor binding protein 1: functional role of transcription factor HNF1 in vivo, Proc. Natl. Acad. Sci. U.S.A., 90, 272, 10.1073/pnas.90.1.272 · DOI
  54. Villafuerte, 1994, Coculture of primary rat hepatocytes and nonparenchymal cells permits expression of insulin-like growth factor binding protein-3 in vitro, Endocrinology, 134, 2044, 10.1210/endo.134.5.7512496 · DOI
  55. Chin, 1994, Cellular localization and regulation of gene expression for components of the insulin-like growth factor ternary binding protein complex, Endocrinology, 134, 2498, 10.1210/endo.134.6.7515002 · doi:10.1210/endo.134.6.7515002 · Paper page
  56. Scharf, 1996, Synthesis of insulinlike growth factor binding proteins and of the acid-labile subunit in primary cultures of rat hepatocytes, of Kupffer cells, and in cocultures: regulation by insulin, insulinlike growth factor, and growth hormone, Hepatology, 23, 818, 10.1002/hep.510230424 · doi:10.1002/hep.510230424
  57. Zimmermann, 2000, Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver, Am. J. Physiol. Gastr. Liver Physiol., 278, G447, 10.1152/ajpgi.2000.278.3.G447 · doi:10.1152/ajpgi.2000.278.3.g447
  58. Villafuerte, 1992, Nutrition and somatomedin. XXIX. Molecular regulation of IGFBP-1 in hepatocyte primary culture, Diabetes, 41, 835, 10.2337/diab.41.7.835 · doi:10.2337/diab.41.7.835
  59. Pao, 1993, Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding protein 1 gene transcription by hormones and provision of amino acids in rat hepatocytes, Mol. Endocrinol., 7, 1561
  60. Caro, 1988, Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver, J. Clin. Invest., 81, 976, 10.1172/JCI113451 · DOI · Paper page
  61. Zindy, 1992, Expression of insulin-like growth factor II (IGF-II) and IGF-II, IGF-I and insulin receptors mRNAs in isolated non-parenchymal rat liver cells, J. Hepatol., 14, 30, 10.1016/0168-8278(92)90127-B · DOI
  62. Brenzel, 1996, Characterization of insulin-like growth factor (IGF)-I-receptor binding sites during in vitro transformation of rat hepatic stellate cells to myofibroblasts, Eur. J. Clin. Chem. Clin. Biochem., 34, 401
  63. Moller, 1989, Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man, Mol. Endocrinol., 3, 1263, 10.1210/mend-3-8-1263 · DOI · Paper page
  64. Frasca, 1999, Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells, Mol. Cell Biol., 19, 3278, 10.1128/MCB.19.5.3278 · DOI · Paper page
  65. MacDonald, 1989, Serum form of the rat insulin-like growth factor II/mannose 6-phosphate receptor is truncated in the carboxyl-terminal domain, J. Biol. Chem., 264, 3256, 10.1016/S0021-9258(18)94060-3 · DOI
  66. Bobek, 1992, Radioimmunoassay of soluble insulin-like growth factor-II/mannose 6-phosphate receptor: developmental regulation of receptor release by rat tissues in culture, Endocrinology, 130, 3387, 10.1210/endo.130.6.1317782 · doi:10.1210/endo.130.6.1317782
  67. Scott, 1996, Soluble insulin-like growth factor-II/mannose 6-P receptor inhibits deoxyribonucleic acid synthesis in cultured rat hepatocytes, Endocrinology, 137, 873, 10.1210/endo.137.3.8603597 · DOI
  68. Mazziotti, 2002, Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study, Cancer, 95, 2539, 10.1002/cncr.11002 · DOI
  69. Park, 1995, Differential expression of transforming growth factor alpha and insulin-like growth factor II in chronic active hepatitis B, cirrhosis and hepatocellular carcinoma, J. Hepatol., 22, 286, 10.1016/0168-8278(95)80281-9 · doi:10.1016/0168-8278(95)80281-9
  70. Price, 2002, Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma, Hepatology, 36, 1089, 10.1053/jhep.2002.36158 · DOI
  71. Scharf, 2000, Analysis of the IGF axis in preneoplastic hepatic foci and hepatocellular neoplasms developing after low-number pancreatic islet transplantation into the livers of streptozotocin diabetic rats, Lab. Invest., 80, 1399, 10.1038/labinvest.3780147 · DOI
  72. Cariani, 1988, Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis, Cancer Res., 48, 6844
  73. Su, 1994, Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B virus antigen expression, Hepatology, 20, 788, 10.1002/hep.1840200404 · DOI
  74. Sedlaczek, 2003, Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis, Br. J. Cancer, 88, 733, 10.1038/sj.bjc.6600777 · DOI
  75. Nardone, 1996, Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma, Hepatology, 23, 1304, 10.1002/hep.510230602 · DOI
  76. Kim, 1998, Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma, Cancer Res., 58, 348
  77. Schirmacher, 1992, Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth, Cancer Res., 52, 2549
  78. Liu, 1997, Hepatocarcinogenesis in woodchuck hepatitis virus/c-myc mice: sustained cell proliferation and biphasic activation of insulin-like growth factor II, Hepatology, 25, 874, 10.1002/hep.510250415 · DOI
  79. Sohda, 1996, Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level, Lab. Invest., 75, 307
  80. Aihara, 1998, Allelic imbalance of insulin-like growth factor II gene expression in cancerous and precancerous lesions of the liver, Hepatology, 28, 86, 10.1002/hep.510280113 · doi:10.1002/hep.510280113
  81. Takeda, 1996, Allelic-expression imbalance of the insulin-like growth factor 2 gene in hepatocellular carcinoma and underlying disease, Oncogene, 12, 1589
  82. Lin, 1997, Antisense oligodeoxynucleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II, J. Biochem. (Tokyo), 122, 717, 10.1093/oxfordjournals.jbchem.a021814 · DOI
  83. Eriksson, 2001, Methylation changes in the human IGF2 p3 promoter parallel IGF2 expression in the primary tumor, established cell line, and xenograft of a human hepatoblastoma, Exp. Cell Res., 270, 88, 10.1006/excr.2001.5336 · DOI
  84. Lee, 1998, The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter 4, Oncogene, 16, 2367, 10.1038/sj.onc.1201760 · DOI
  85. Kang-Park, 2001, Activation of the IGF-II gene by HBV-X protein requires PKC and p44/p42 map kinase signalings, Biochem. Biophys. Res. Commun., 283, 303, 10.1006/bbrc.2001.4767 · DOI
  86. Kang-Park, 2003, PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells, FEBS Lett., 545, 203, 10.1016/S0014-5793(03)00535-0 · DOI
  87. Lee, 2000, Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma, Oncogene, 19, 3717, 10.1038/sj.onc.1203694 · DOI
  88. Hankins, 1996, M6P/IGF2 receptor: a candidate breast tumor suppressor gene, Oncogene, 12, 2003
  89. Piao, 1997, Deletion of the M6P/IGF2r gene in primary hepatocellular carcinoma, Cancer Lett., 120, 39, 10.1016/S0304-3835(97)00289-9 · DOI
  90. Byrd, 1999, Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations, J. Biol. Chem., 274, 24408, 10.1074/jbc.274.34.24408 · DOI
  91. Devi, 1999, Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers, Cancer Res., 59, 4314
  92. Yamada, 1997, Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis, Proc. Natl. Acad. Sci. U.S.A., 94, 10351, 10.1073/pnas.94.19.10351 · DOI · Paper page
  93. De Souza, 1997, Imprinted genes in liver carcinogenesis, Faseb J., 11, 60, 10.1096/fasebj.11.1.9034167 · doi:10.1096/fasebj.11.1.9034167
  94. Jirtle, 1993, Increased mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor beta 1 levels during monoterpene-induced regression of mammary tumors, Cancer Res., 53, 3849
  95. Yang, 2003, Effects of insulin-like growth factors-IR and -IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cells, J. Gastroenterol. Hepatol., 18, 296, 10.1046/j.1440-1746.2003.02961.x · doi:10.1046/j.1440-1746.2003.02961.x
  96. Gong, 2000, The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma, Mol. Cell Biochem., 207, 101, 10.1023/A:1007010818094 · DOI
  97. Huynh, 2002, A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation, Cell Growth Differ., 13, 115
  98. Gray, 2000, Altered expression of members of the IGF-axis in hepatoblastomas, Br. J. Cancer, 82, 1561, 10.1054/bjoc.1999.1179 · DOI
  99. Scharf, 1998, Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC), Carcinogenesis, 19, 2121, 10.1093/carcin/19.12.2121 · DOI
  100. Baxter, 2001, Signalling pathways involved in antiproliferative effects of IGFBP-3: a review, Mol. Pathol., 54, 145, 10.1136/mp.54.3.145 · doi:10.1136/mp.54.3.145
  101. Hanafusa, 2002, Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma, Cancer Lett., 176, 149, 10.1016/S0304-3835(01)00736-4 · DOI
  102. Lee, 1993, Insulin-like growth factor (IGF) suppression of IGFBP-1 production: evidence for mediation by the type I IGF receptor, Regul. Peptides, 48, 199, 10.1016/0167-0115(93)90348-C · DOI
  103. Brouillet, 1991, Increased plasma cathepsin D concentration in hepatic carcinoma and cirrhosis but not in breast cancer, Clin. Biochem., 24, 491, 10.1016/S0009-9120(05)80008-6 · doi:10.1016/s0009-9120(05)80008-6
  104. Perks, 2003, Actions of IGFBP on epithelial cancer cells: potential for new therapeutic targets, Horm. Metab. Res., 35, 828, 10.1055/s-2004-814139 · doi:10.1055/s-2004-814139
  105. Martin, 1999, Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1, J. Cell Biol., 146, 881, 10.1083/jcb.146.4.881 · DOI
  106. Werner, 2003, The IGFI receptor gene: a molecular target for disrupted transcription factors, Genes Chromosomes Cancer, 36, 113, 10.1002/gcc.10157 · DOI
  107. Tsai, 1988, Evidence of autocrine regulation in human hepatoma cell lines, Biochem. Biophys. Res. Commun., 153, 39, 10.1016/S0006-291X(88)81186-0 · DOI
  108. Verspohl, 1988, Insulin and insulin-like growth factor I regulate the same biological functions in HEP-G2 cells via their own specific receptors, J. Clin. Endocrinol. Metab., 67, 169, 10.1210/jcem-67-1-169 · doi:10.1210/jcem-67-1-169
  109. Lee, 2003, Activation of insulin-like growth factor II signaling by mutant type p53: physiological implications for potentiation of IGF-II signaling by p53 mutant 249, Mol. Cell Endocrinol., 203, 51, 10.1016/S0303-7207(03)00117-5 · DOI
  110. Kim, 1996, Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product, Cancer Res., 56, 3831
  111. Tao, 2000, Hepatitis B virus X protein activates expression of IGF-IR and VEGF in hepatocellular carcinoma cells, Zhonghua Gan Zang Bing Za Zhi, 8, 161
  112. Tanaka, 1997, Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes, Hepatology, 26, 598, 10.1002/hep.510260310 · DOI
  113. Nishiyama, 1992, Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma, Biochem. Biophys. Res. Commun., 183, 280, 10.1016/0006-291X(92)91640-C · DOI
  114. Tanaka, 1996, Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis, Cancer Res., 56, 3391
  115. Coutant, 2002, PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival, Hepatology, 36, 1079, 10.1053/jhep.2002.36160 · DOI
  116. Stambolic, 1998, Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN, Cell, 95, 29, 10.1016/S0092-8674(00)81780-8 · DOI · Paper page
  117. Yao, 1999, PTEN/MMAC1 mutations in hepatocellular carcinomas, Oncogene, 18, 3181, 10.1038/sj.onc.1202659 · DOI
  118. Kawamura, 1999, PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors, Jpn. J. Cancer Res., 90, 413, 10.1111/j.1349-7006.1999.tb00763.x · DOI
  119. Yakicier, 2001, Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma, Oncogene, 20, 5232, 10.1038/sj.onc.1204674 · doi:10.1038/sj.onc.1204674
  120. Nakamura, 1998, Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3beta and APC and reduces the beta-catenin level, Genes Cells, 3, 395, 10.1046/j.1365-2443.1998.00198.x · DOI · Paper page
  121. de La Coste, 1998, Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas, Proc. Natl. Acad. Sci. U.S.A., 95, 8847, 10.1073/pnas.95.15.8847 · DOI · Paper page
  122. Nhieu, 1999, Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation, Am. J. Pathol., 155, 703, 10.1016/S0002-9440(10)65168-1 · DOI · Paper page
  123. Miyoshi, 1998, Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3, Cancer Res., 58, 2524
  124. Devereux, 1999, Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis, Oncogene, 18, 4726, 10.1038/sj.onc.1202858 · DOI
  125. Satoh, 2000, AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1, Nat. Genet., 24, 245, 10.1038/73448 · DOI · Paper page
  126. Phillips, 1978, The interaction of daunomycin with polydeoxynucleotides, Eur. J. Biochem., 85, 487, 10.1111/j.1432-1033.1978.tb12264.x · doi:10.1111/j.1432-1033.1978.tb12264.x
  127. Zunina, 1975, The inhibition in vitro of DNA polymerase and RNA polymerases by daunomycin and adriamycin, Biochem. Pharmacol., 24, 309, 10.1016/0006-2952(75)90300-7 · doi:10.1016/0006-2952(75)90300-7
  128. Bachur, 1978, A general mechanism for microsomal activation of quinone anticancer agents to free radicals, Cancer Res., 38, 1745
  129. Bates, 1982, Deoxyribose breakdown by the adriamycin semiquinone and H2O2: evidence for hydroxyl radical participation, FEBS Lett., 145, 137, 10.1016/0014-5793(82)81222-2 · DOI
  130. Phillips, 1989, DNA sequence-specific adducts of adriamycin and mitomycin C, FEBS Lett., 246, 233, 10.1016/0014-5793(89)80289-3 · doi:10.1016/0014-5793(89)80289-3
  131. Bachur, 1992, Helicase inhibition by anthracycline anticancer agents, Mol. Pharmacol., 41, 993, 10.1016/S0026-895X(25)09287-9 · DOI
  132. Ross, 1981, DNA double-stranded breaks in mammalian cells after exposure to intercalating agents, Biochim. Biophys. Acta, 654, 129, 10.1016/0005-2787(81)90145-3 · DOI · Paper page
  133. Triton, 1982, The anticancer agent adriamycin can be actively cytotoxic without entering cells, Science, 217, 248, 10.1126/science.7089561 · DOI · Paper page
  134. Vichi, 1992, Adriamycin: protection from cell death by removal of extracellular drug, Cancer Res., 52, 4135
  135. Gewirtz, 1999, A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin, Biochem. Pharmacol., 57, 727, 10.1016/S0006-2952(98)00307-4 · DOI · Paper page
  136. Herr, 2001, Cellular stress response and apoptosis in cancer therapy, Blood, 98, 2603, 10.1182/blood.V98.9.2603 · DOI · Paper page
  137. Chen, 1996, Persistent activation of c-Jun N-terminal kinase 1 (JNK1) in gamma radiation-induced apoptosis, J. Biol. Chem., 271, 631, 10.1074/jbc.271.2.631 · DOI · Paper page
  138. Herr, 1999, JNK/SAPK activity contributes to TRAIL-induced apoptosis, Cell Death Differ., 6, 130, 10.1038/sj.cdd.4400467 · DOI
  139. Eichhorst, 2000, A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs, Mol. Cell Biol., 20, 7826, 10.1128/MCB.20.20.7826-7837.2000 · DOI
  140. Venot, 1998, The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression, EMBO J., 17, 4668, 10.1093/emboj/17.16.4668 · DOI · Paper page
  141. Zhu, 1998, Identification of a novel p53 functional domain that is necessary for mediating apoptosis, J. Biol. Chem., 273, 13030, 10.1074/jbc.273.21.13030 · DOI · Paper page
  142. Testi, 1996, Sphingomyelin breakdown and cell fate, Trends Biochem. Sci., 21, 468, 10.1016/S0968-0004(96)10056-6 · DOI · Paper page
  143. Cuvillier, 1996, Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate, Nature, 381, 800, 10.1038/381800a0 · DOI · Paper page
  144. Spiegel, 1998, Sphingosine-1-phosphate in cell growth and cell death, Ann. NY Acad. Sci., 845, 11, 10.1111/j.1749-6632.1998.tb09658.x · DOI · Paper page
  145. Malisan, 1999, Lipid signaling in CD95-mediated apoptosis, FEBS Lett., 452, 100, 10.1016/S0014-5793(99)00543-8 · DOI
  146. Abbadie, 1993, High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro, Cell, 75, 899, 10.1016/0092-8674(93)90534-W · DOI · Paper page
  147. Jeremias, 1998, Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells, Blood, 91, 4624, 10.1182/blood.V91.12.4624 · DOI · Paper page
  148. Beg, 1996, An essential role for NF-kappaB in preventing TNF-alpha-induced cell death, Science, 274, 782, 10.1126/science.274.5288.782 · DOI · Paper page
  149. Bash, 1997, c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition, Mol. Cell Biol., 17, 6526, 10.1128/MCB.17.11.6526 · DOI
  150. Zinszner, 1998, CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum, Genes Dev., 12, 982, 10.1101/gad.12.7.982 · DOI · Paper page
  151. Kaufman, 1999, Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls, Genes Dev., 13, 1211, 10.1101/gad.13.10.1211 · DOI · Paper page
  152. Jiang, 1999, Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways, Hepatology, 29, 101, 10.1002/hep.510290102 · DOI
  153. Qin, 2002, Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells, Cancer Lett., 175, 27, 10.1016/S0304-3835(01)00720-0 · DOI
  154. Lee, 2002, Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines, Cancer Chemother. Pharmacol., 49, 78, 10.1007/s00280-001-0376-4 · doi:10.1007/s00280-001-0376-4
  155. Ballif, 2001, Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals, Cell Growth Differ., 12, 397
  156. Lee, 2002, The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia, Leukemia, 16, 486, 10.1038/sj.leu.2402460 · DOI · Paper page
  157. Ito, 1998, Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma, Hepatology, 27, 951, 10.1002/hep.510270409 · DOI · Paper page
  158. Hoshino, 1999, Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors, Oncogene, 18, 813, 10.1038/sj.onc.1202367 · DOI · Paper page
  159. Brenner, 1997, Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153, J. Biol. Chem., 272, 22173, 10.1074/jbc.272.35.22173 · DOI · Paper page
  160. Guyton, 1996, Activation of mitogen-activated protein kinase by H2O2. Role in cell survival following oxidant injury, J. Biol. Chem., 271, 4138, 10.1074/jbc.271.8.4138 · DOI · Paper page
  161. Wang, 1998, The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival, Biochem. J., 333, 291, 10.1042/bj3330291 · DOI · Paper page
  162. Huynh, 2003, Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis, BMC Gastroenterol., 3, 19, 10.1186/1471-230X-3-19 · DOI · Paper page
  163. Mitsui, 2001, The MEK1-ERK map kinase pathway and the PI 3-kinase-Akt pathway independently mediate anti-apoptotic signals in HepG2 liver cancer cells, Int. J. Cancer, 92, 55, 10.1002/1097-0215(200102)9999:9999<::AID-IJC1143>3.0.CO;2-O · doi:10.1002/1097-0215(200102)9999:9999<::aid-ijc1143>3.0.co;2-o
  164. Wang, 2000, Requirement for ERK activation in cisplatin-induced apoptosis, J. Biol. Chem., 275, 39435, 10.1074/jbc.M004583200 · DOI · Paper page
  165. Persons, 1999, Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin, Clin. Cancer Res., 5, 1007
  166. Gao, 1995, Sensitivity of anticancer drugs in NIH3T3′ cells transfected with oncogenes accompanied by pSV2neo vector, Anticancer Res., 15, 1911
  167. MacKeigan, 2000, MEK inhibition enhances paclitaxel-induced tumor apoptosis, J. Biol. Chem., 275, 38953, 10.1074/jbc.C000684200 · DOI · Paper page
  168. Mikula, 2003, The proto-oncoprotein c-Fos negatively regulates hepatocellular tumorigenesis, Oncogene, 22, 6725, 10.1038/sj.onc.1206781 · DOI
  169. Fokstuen, 1997, The Ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell line, Anticancer Res., 17, 2347
  170. Viktorsson, 2000, Increased apoptosis and increased clonogenic survival of 12V-H-ras transformed rat fibroblasts in response to cisplatin, Apoptosis, 5, 355, 10.1023/A:1009639726168 · doi:10.1023/a:1009639726168
  171. Muller, 1997, Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53, J. Clin. Invest., 99, 403, 10.1172/JCI119174 · DOI · Paper page
  172. Rokudai, 2000, Cleavage and inactivation of antiapoptotic Akt/PKB by caspases during apoptosis, J. Cell Physiol., 182, 290, 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8 · DOI
  173. Qin, 2002, Gene expression profiling by cDNA array in human hepatoma cell line in response to cisplatin treatment, Life Sci., 70, 1677, 10.1016/S0024-3205(01)01554-5 · doi:10.1016/s0024-3205(01)01554-5
  174. Oka, 2002, M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan, Hepatology, 35, 1153, 10.1053/jhep.2002.32669 · DOI
  175. Prasad, 1997, CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein, Proc. Natl. Acad. Sci. U.S.A., 94, 6346, 10.1073/pnas.94.12.6346 · DOI · Paper page
  176. Brantley-Finley, 2003, The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide, Biochem. Pharmacol., 66, 459, 10.1016/S0006-2952(03)00255-7 · DOI

Cited by

See all 191

Metadata

Authors
Alexia, C., Fallot, G., Lasfer, M., Schweizer-Groyer, G., & Groyer, A.
Venue
Biochemical Pharmacology
Publisher
Elsevier BV
Published
2004-09
Volume
68
Issue
6
Pages
1003-1015
ISSN
0006-2952 (ISSN-L)
OpenAlex
W2021625611
Cited by
191
References
4
FWCI
5.53
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. https://app.cochat.ai/papers/10.1016/j.bcp.2004.05.029
The paper
Alexia, C., Fallot, G., Lasfer, M., Schweizer-Groyer, G., & Groyer, A. (2004). An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2004.05.029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.